Clinical Trials Logo

Schizophrenia clinical trials

View clinical trials related to Schizophrenia.

Filter by:

NCT ID: NCT05635266 Recruiting - Stroke Clinical Trials

A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Start date: October 26, 2021
Study type: Observational

To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.

NCT ID: NCT05628103 Not yet recruiting - Schizophrenia Clinical Trials

A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication

Start date: November 24, 2022
Phase: Phase 3
Study type: Interventional

A clinical study that will evalute how well SEP-363856 works and how safe it is in people with schizophrenia that switch to SEP-363856 from their current antisychotic medication. This study will accept both male and female participants, ages of 18 years to 65 years, with schizophrenia. The study will take place in approxmiately 24 study sites in North America. Particpants should expect to be in the study for up to 12 weeks.

NCT ID: NCT05623228 Recruiting - Schizophrenia Clinical Trials

The Effectiveness and Efficacy of the Combination of the Integrated Psychological Therapy and Metacognitive Training.

Start date: November 1, 2022
Phase: Phase 2
Study type: Interventional

The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia. Is it effective and efficacious?

NCT ID: NCT05622201 Not yet recruiting - Clinical trials for Schizophrenia Spectrum and Other Psychotic Disorders

A Randomized Controlled Trial With Rituximab - for Schizophrenia Spectrum Disorder in Adults

Start date: January 15, 2023
Phase: Phase 2
Study type: Interventional

Immunological factors are assumed to be determinants for some psychiatric disorders, thus anti-inflammatory drugs may be helpful. However, studies on such treatments are scarce. An inflammatory modulating drug rituximab, cluster of differentiation antigen 20 antibodies (anti-CD20 antibodies), is a standard treatment for e.g. multiple sclerosis. The investigators aim to test rituximab in a randomised placebo-controlled double-blinded, add-on treatment trial in 104 participants (18-51 years) with schizophrenia spectrum disorder. Sampling from blood for analyses of inflammatory mediators are investigated at gene and protein levels and resting state functional magnetic resonance imaging (rsfMRI) and lumbar puncture are optional. Biomarkers will be investigated in relation to treatment response.

NCT ID: NCT05603104 Not yet recruiting - Clinical trials for Major Depressive Disorder

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

Start date: August 1, 2023
Phase: Phase 4
Study type: Interventional

Schizophrenia, bipolar and major depressive disorders collectively affect over 10 million people across the EU and are associated with annual healthcare and societal costs in excess of 100 billion Euros. When diagnosed with one of these disorders, patients are prescribed psychotropic medication such as antidepressants, mood stabilisers or antipsychotics. It is unknown whether this first-line treatment will be successful. After this first-line treatment fails, usually a second-line treatment is initiated, and when this is not successful either a third-line treatment is initiated. Third-line treatments are quite successful, especially when compared to second-line treatments. The research question is whether the third-line treatments (early-intensified treatments) would be more efficacious than the current second-line treatments (treatment as usual) for schizophrenia, bipolar and major depressive disorders. If this is indeed the case, this could lead to the prevention of unnecessary trials of ineffective treatments and adaptations of worldwide guidelines as well as a reduction of healthcare and societal costs.

NCT ID: NCT05601063 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Ascertaining Diagnosis Classification With Elicited Speech

Start date: October 1, 2020
Study type: Observational

Cross-sectional observational study of the relationship between speech patterns and psychiatric symptoms and disorders.

NCT ID: NCT05601050 Active, not recruiting - Clinical trials for Schizophrenia and Related Disorders

Linguistic Predictors of Outcomes in Psychosis

Start date: March 4, 2021
Study type: Observational

Longitudinal observational study of the relationship between speech patterns and clinical symptoms in schizophrenia spectrum disorders.

NCT ID: NCT05599373 Recruiting - Schizophrenia Clinical Trials

Optimal rTMS for Cognitive Deficits and Negative Symptoms in Schizophrenia

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Negative symptoms and cognition decline are major challenges in clinical management of schizophrenia. Dorsomedial prefrontal cortex (DLPFC) has been highly involved in the mechanisms of negative symptoms and cognitive symptoms of schizophrenia. However, the effect of repetitive transcranial magnetic stimulation (rTMS) over left or bilateral DLPFC has not yet been well studied. The aim of this study is to describe how the effectiveness of rTMS over different targets for cognitive deficits and negative symptoms in schizophrenia will be evaluated. The study will provide evidence to determine whether a bilateral DLPFC rTMS and is more effective than a left DLPFC rTMS alone to optimize treatment protocol in schizophrenia.

NCT ID: NCT05598450 Recruiting - Schizophrenia Clinical Trials

rTMS for Auditory Hallucinations Guided by Magnetoencephalography

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

Repetitive transcranial magnetic stimulation (rTMS) can increase or decrease cortical excitability in patients with psychosis (such as schizophrenia). Here, we conducted an open clinical trial on 60 schizophrenics with auditory hallucinations. We searched for targets through magnetoencephalography and then intervened to prove that rTMS guided by magnetoencephalography is effective for auditory hallucinations.

NCT ID: NCT05582980 Recruiting - Schizophrenia Clinical Trials

Online HD-tDCS Over the Left DLPFC During a Working Memory Task for Treating Negative Symptoms of Schizophrenia

Start date: June 15, 2020
Phase: N/A
Study type: Interventional

In this randomized double-blind trial, the investigators aim to investigate whether online high definition transcranial direct current stimulation (HD-tDCS) over the left dorsolateral prefrontal cortex (DLPFC) during a working memory task improves the severity of negative symptoms in schizophrenia patients with predominant negative symptoms.